Medtronic PLC vs Ralph Lauren Corp — how do they compare? Medtronic PLC trades at $87.9 (market cap $109.38B), while Ralph Lauren Corp trades at $368.77 (market cap $21.52B). The key difference: Medtronic PLC is far larger — about 5.1× Ralph Lauren Corp's market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Ralph Lauren Corp for 84 Days on average.
| MDT | RL | |
|---|---|---|
Market Cap | $109.38B | $21.52B |
Volume | 55,890,185 | 454,217 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $414.25 |
52-Week Low | $73.75 | $309.29 |
Typical Hold Time | 63 Days | 84 Days |
Enterprise Value | $128.71B | $22.58B |
Dividend Yield | 3.37% | 1.11% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 exceeding the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent developments include global store expansion and sustainability initiatives under the Timeless by Design 2030 strategy.
RL presents a compelling investment case with strong profitability (37.54% ROE, 70.27% gross margins) and analyst consensus pointing to 26% upside to the $456.67 price target. However, the stock faces near-term technical headwinds and competitive pressures in the luxury apparel sector. The improving cash flow trajectory and dividend payments provide shareholder value support amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →